Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia

被引：27
|
作者：
Yoest, Jennifer M. [1 ]
Shirai, Cara Lunn [2 ]
Duncavage, Eric J. [2 ]
机构：
[1] Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA
[2] Washington Univ, Dept Pathol & Immunol, St Louis, MO 63110 USA
来源：
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY | 2020年 / 8卷
关键词：
measurable (minimal) residual disease; acute myeloid leukemia; next generation sequencing; unique molecular identifier; error-corrected sequencing; clinical applications of NGS; AML MRD; QUANTITATIVE RT-PCR; CLONAL HEMATOPOIESIS; TANDEM DUPLICATION; INDUCTION THERAPY; RARE MUTATIONS; DIGITAL PCR; RISK; AML; DIAGNOSIS; TRANSPLANTATION;
D O I：
10.3389/fcell.2020.00249
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications.
引用
收藏
页数：10
相关论文
共 50 条
  • [1] Perspective on measurable residual disease testing in acute myeloid leukemia
    Walter, Roland B.
    LEUKEMIA, 2024, 38 (01) : 10 - 13
  • [2] Measurable Residual Disease Testing Using Next-Generation Sequencing in Acute Myeloid Leukemia
    Kim, Seon Young
    Huh, Hee Jin
    ANNALS OF LABORATORY MEDICINE, 2023, 43 (04) : 323 - 324
  • [3] Development of a Next-generation Sequencing-based Gene Panel Test to Detect Measurable Residual Disease in Acute Myeloid Leukemia
    Kim, Jin Ju
    Jang, Ji Eun
    Lee, Hyeon Ah
    Park, Mi Ri
    Kook, Hye Won
    Lee, Seung-Tae
    Choi, Jong Rak
    Min, Yoo Hong
    Shin, Saeam
    Cheong, June -Won
    ANNALS OF LABORATORY MEDICINE, 2023, 43 (04) : 328 - 336
  • [4] Next generation sequencing-based monitoring for minimal residual disease in acute myeloid leukemia
    Ok, Chi Young
    Salim, Alaa
    Luthra, Rajyalakshmi
    Patel, Keyur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S196 - S196
  • [5] The present and future of measurable residual disease testing in acute myeloid leukemia
    Blachly, James S.
    Walter, Roland B.
    Hourigan, Christopher S.
    HAEMATOLOGICA, 2022, 107 (12) : 2810 - 2822
  • [6] Measurable residual disease testing for personalized treatment of acute myeloid leukemia
    Ehinger, Mats
    Pettersson, Louise
    APMIS, 2019, 127 (05) : 337 - 351
  • [7] Tracking Measurable Residual Disease in Acute Myeloid Leukemia with Error Corrected Sequencing
    D'Angelo, J.
    Huang, Y.
    Kebede, Y.
    Miick, S.
    Salva, N.
    Troung, C.
    Turner, S.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (10): : S38 - S38
  • [8] Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia
    Dillon, Laura W.
    Higgins, Jake
    Nasif, Hassan
    Othus, Megan
    Beppu, Lan
    Smith, Thomas H.
    Schmidt, Elizabeth
    Valentine III, Charles C.
    Salk, Jesse J.
    Wood, Brent L.
    Erba, Harry P.
    Radich, Jerald P.
    Hourigan, Christopher S.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 401 - 410
  • [9] Evaluating measurable residual disease in acute myeloid leukemia
    Ravandi, Farhad
    Walter, Roland B.
    Freeman, Sylvie D.
    BLOOD ADVANCES, 2018, 2 (11) : 1356 - 1366
  • [10] Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia
    Dillon, Laura W.
    Higgins, Jake
    Nasif, Hassan
    Othus, Megan
    Beppu, Lan
    Smith, Thomas H.
    Schmidt, Elizabeth
    Valentine III, Charles C.
    Salk, Jesse J.
    Wood, Brent L.
    Erba, Harry P.
    Radich, Jerald P.
    Hourigan, Christopher S.
    HAEMATOLOGICA, 2024, 109 (02) : 401 - 410
12345